21
4
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T67991 |
Iliparcil
|
Others | Others |
Iliparcil 是一种具有口服活性的抗血栓化合物。 | |||
T4076 |
Fondaparinux sodium
Natural heparin pentasaccharide Sodium,Fondaparin sodium,磺达肝素(癸)钠,磺达肝癸钠,SR-90107A,Arixtra |
Factor Xa | Metabolism |
Fondaparinux sodium (SR-90107A) 是抗凝血酶依赖性的 factor Xa 抑制剂。 | |||
T13210 |
Trombodipine
PCA-4230 |
Antibiotic | Microbiology/Virology |
Trombodipine (PCA-4230) 是一种血小板聚集抑制剂,具有抗血栓活性,对单核细胞增生李斯特菌具有保护作用。 | |||
T80792 |
WAY-639228
|
Others | Others |
WAY-639228-A 具有潜在的抗血栓和抗凝活性,可用于研究脑血栓。 | |||
T25741 |
Linotroban
HN 11500,CL-871502 |
PPAR | DNA Damage/DNA Repair; Metabolism |
Linotroban(CL-871502) 是一种有效的选择性血栓素(TXA2)受体拮抗剂,具有抗血栓活性。 | |||
T27318 |
Fidexaban
CI-1031,BX-807834,PD-200022,CI1031,BX807834,ZK-807834 |
Factor Xa | Metabolism |
Fidexaban (CI1031) 是一种新型、强效、选择性和口服活性 Xa 因子抑制剂,在多种测定中均显示出抗血栓活性。 | |||
T27920 |
LY 517717
LY-517717,LY517717 |
Factor Xa | Metabolism |
LY 517717 是一种具有口服活性的凝血因子 Xa 抑制剂,具有抗血栓活性,可用于研究静脉血栓栓塞(VTE)。 | |||
T17025 |
Tecarfarin
ATI-5000,ATI-5923 |
Others | Others |
Tecarfarin (ATI-5923) 是一种具有口服活性和有效性的维生素 K 环氧化物还原酶 (VKOR) 拮抗剂和大麻素-1受体反向激动剂,具有抗血栓形成活性,可减轻小鼠的腹痛并增加肠道转运。 | |||
T63966 |
BMS-986141
UDM-003183 |
Protease-activated Receptor | GPCR/G Protein |
BMS-986141(UDM-003183) 是一种具有口服活性的选择性和高效性的凝血酶受体蛋白酶激活受体-4 (protease-activated receptor-4 (PAR-4)) 拮抗剂,其 IC50 值为 0.4 nM。BMS-98614 表现出显著的抗血栓作用。 | |||
T17024 |
Tecarfarin sodium
ATI-5923 sodium |
Others | Others |
Tecarfarin sodium is a novel orally active non-competitive vitamin K epoxide reductase antagonist. Tecarfarin sodium has the antithrombotic activity. | |||
T17091 | Thrombin Inhibitor 2 | Others | Others |
Thrombin Inhibitor 2 is a small molecule direct thrombin inhibitor. Thrombin Inhibitor 2 has antithrombotic activity. | |||
T70458 | FXIa-6f | ||
FXIa-6f is a high affinity, orally bioavailable macrocyclic FXIa inhibitor with antithrombotic activity in preclinical species | |||
T70909 |
AY 31390
|
||
AY 31390 is a phosphodiesterase (PDE) inhibitor with antithrombotic activity. | |||
T12694 |
Razaxaban hydrochloride
BMS 561389 hydrochloride,DPC 906 hydrochloride |
Others | Others |
Razaxaban hydrochloride is a highly potent, selective and orally active inhibitor of factor Xa(Ki of 0.19 nM),has strongly antithrombotic activity. | |||
T12782 |
RWJ-445167
3DP-10017 |
Factor Xa; Thrombin | Metabolism; Proteases/Proteasome |
RWJ-445167 is a thrombin and factor Xa dual inhibitor(Ki of 4.0 nM and 230 nM, respectively), with potent antithrombotic activity. | |||
T16377 |
Odiparcil
SB-424323 |
Thrombin | Proteases/Proteasome |
Odiparcil is an orally active beta-d-thioxyloside analog. Odiparcil is an indirect thrombin inhibitor that exerts its anticoagulant effect through activation of antithrombin II (heparin cofactor II). It also has an antithrombotic activity associated with a reduced risk of adverse bleeding events. | |||
T33579 |
Nafazatrom
Nafazatromum |
||
Nafazatrom is a pyrazolinone derivative and lipoxygenase inhibitor that increases endogenous prostacyclin (PGI2) and has experimental anticancer activity. Nafazatrom is also an antithrombotic drug that increases prostacyclin levels and reduces the inciden | |||
T36759 |
SAR 216471 hydrochloride
|
||
Potent P2Y12 antagonist (IC50 = 17 nM). Displays antiplatelet and antithrombotic activity in vivo. Orally available. Boldron et al (2014) N-[6-(4-butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide (SAR216471), a novel intravenous and oral, reversible, and directly acting P2Y12 antagonist. J.Med.Chem. 57 7293 PMID:25075638 | |||
T81791 |
MIPS-21335
|
PI4K | PI3K/Akt/mTOR signaling |
MIPS-21335为PI3KC2α抑制剂(IC50:0.007 μM),亦能抑制PI3KC2β、p110α、p110β及p110δ(IC50分别为0.043、0.140、0.386、0.742 μM)。本化合物展现出抗血栓作用。 | |||
T79847 |
Frunexian
EP-7041 |
Factor Xa | Metabolism |
Frunexian (EP-7041) 为针对 Factor XIa 的选择性有效凝血因子 XI/活化因子 XI 抑制剂,展现抗血栓活性,且在大鼠肠系膜动脉穿刺模型中显示出无出血倾向。此化合物亦可应用于体外膜氧合(ECMO)的研究领域。 | |||
T61811 |
GPVI antagonist 3
|
||
GPVI antagonist 3 (Compound 2) is a potential antagonist that shows promising antiplatelet activity by selectively inhibiting the interaction between the Glycoprotein VI (GPVI) receptor and its ligands. It demonstrates potent inhibitory effects, with IC50 values of 1.01 μM for collagen, 1.92 μM for CRP, 7.24 μM for convulxin, and 51.74 μM for thrombin. GPVI is a major collagen receptor on platelets, making it an ideal target for safe and effective antithrombotic treatment. Therefore, GPVI antago... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T4853 |
TRIA-662
3-Carbamoyl-1-methylpyridinium Chloride,3-氨基甲酰-1-甲基氯化吡啶,1-Methylnicotinamide chloride,1-methylpyridin-1-ium-3-carboxamide hydrochloride,Nicotinamide Chloromethylate |
Others; Endogenous Metabolite | Metabolism; Others |
TRIA-662 (Nicotinamide Chloromethylate) 是内源性代谢产物的一种。 | |||
T2S0504 |
Ilexoside D
|
Others | Others |
Ilexoside D has ant-allergic, and anti-coagulant activities, it shows anti-tissue factor activity as well as the antithrombotic activity. | |||
T13302 |
Viquidil hydrochloride
Quinotoxine hydrochloride |
Others | Others |
Viquidil hydrochloride (Quinotoxine hydrochloride) 是奎尼丁的同分异构体,是一种脑血管扩张剂,具有抗血栓作用。 | |||
TN1996 |
Nothofagin
|
ERK; IL Receptor; TNF | Apoptosis; Immunology/Inflammation; MAPK |
Nothofagin 具有抗氧化和抗血栓活性,它通过抑制高渗透性、CAMs 的表达以及白细胞的粘附和迁移具有抗炎活性,从而支持其作为血管炎症性疾病的治疗作用。 |